25 results on '"van Delft, Yvon"'
Search Results
2. Efficacy and safety of dolutegravir or darunavir in combination with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection (NADIA): week 96 results from a prospective, multicentre, open-label, factorial, randomised, non-inferiority trial
3. Changes in Patient-reported Neuropsychiatric Outcomes during the SENSE Trial: First-line Treatment with Two Nucleoside Analogues plus Etravirine or Efavirenz
4. Pharmacokinetic Interaction Between Etravirine or Rilpivirine and Telaprevir in Healthy Volunteers: A Randomized, Two-way Crossover Trial
5. Sensitive testing of plasma HIV-1 RNA and Sanger sequencing of cellular HIV-1 DNA for the detection of drug resistance prior to starting first-line antiretroviral therapy with etravirine or efavirenz
6. Can we stop CD4+ testing in patients with HIV-1 RNA suppression on antiretroviral treatment?
7. Pharmacokinetics and Pharmacodynamics of Etravirine 400 mg Once Daily in Treatment-Naïve Patients
8. Dynamics of Cellular HIV-1 DNA Levels Over 144 Weeks of Darunavir/Ritonavir Monotherapy Versus Triple Therapy in the MONET Trial
9. Interleukin-6 and C-reactive protein levels after 3 years of treatment with darunavir/ritonavir monotherapy or darunavir/ritonavir + two nucleoside reverse transcriptase inhibitors in the MONET trial
10. A comparison of neuropsychiatric adverse events during 12 weeks of treatment with etravirine and efavirenz in a treatment-naive, HIV-1-infected population
11. Neuropsychiatric Adverse Events With Ritonavir-Boosted Darunavir Monotherapy in HIV-Infected Individuals: A Randomised Prospective Study
12. The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml
13. Switching at Low HIV-1 RNA into Fixed Dose Combinations: TDF/FTC/RPV is non-inferior to TDF/FTC/EFV in first-line suppressed patients living with HIV
14. Etravirine as a Switching Option for Patients with HIV RNA Suppression: A Review of Recent Trials
15. Efficacy of Once Daily Darunavir/Ritonavir in PI-Naïve, NNRTI-Experienced Patients in the ODIN Trial
16. No Difference in the Rate of Change in Telomere Length or Telomerase Activity in HIV-Infected Patients after Three Years of Darunavir/Ritonavir with and without Nucleoside Analogues in the MONET Trial
17. The PROTEA trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV-1 RNA below 50 copies/mL
18. Analysis of drug resistance during HIV RNA viraemia in the MONET trial of darunavir/ritonavir monotherapy
19. Transcript analysis of 250 novel yeast genes from chromosome XIV
20. Transcript analysis of 1003 novel yeast genes using high-throughput northern hybridizations.
21. Can we stop CD4testing in patients with HIV-1 RNA suppression on antiretroviral treatment
22. Time to HIV-1 RNA suppression below 5 copies/ml during first-line protease inhibitor-based antiretroviral treatment - any impact of residual viremia on treatment success?
23. Research letter: is monitoring for CD4 counts still needed for the management of patients with long-term HIV RNA suppression?
24. Interpretation of resistance data from randomized trials of first-line antiretroviral treatment.
25. Impact of hepatitis C co-infection on response to antiretroviral treatment.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.